These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 4015950

  • 41. The influence of CGS 16949A on peripheral aromatisation in breast cancer patients.
    Lønning PE, Jacobs S, Jones A, Haynes B, Powles T, Dowsett M.
    Br J Cancer; 1991 May; 63(5):789-93. PubMed ID: 1828173
    [Abstract] [Full Text] [Related]

  • 42. Additive effects of aminoglutethimide, testololactone, and 4-hydroxyandrostenedione as inhibitors of aromatase.
    Santner SJ, Rosen H, Osawa Y, Santen RJ.
    J Steroid Biochem; 1984 Jun; 20(6A):1239-42. PubMed ID: 6748639
    [Abstract] [Full Text] [Related]

  • 43. Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment.
    Lønning PE, Dowsett M, Jones A, Ekse D, Jacobs S, McNeil F, Johannessen DC, Powles TJ.
    Breast Cancer Res Treat; 1992 Jun; 23(1-2):57-62. PubMed ID: 1446052
    [Abstract] [Full Text] [Related]

  • 44. Low dose aminoglutethimide without hydrocortisone for the treatment of advanced postmenopausal breast cancer.
    Bruning PF, Bonfrer JM, Hart AA, van der Linden E, de Jong-Bakker M, Moolenaar AJ, Nooijen WJ.
    Eur J Cancer Clin Oncol; 1989 Feb; 25(2):369-76. PubMed ID: 2702989
    [Abstract] [Full Text] [Related]

  • 45. Effects of aminoglutethimide on plasma estrone sulfate not caused by aromatase inhibition.
    Lønning PE, Johannessen DC, Thorsen T, Ekse D.
    J Steroid Biochem; 1989 Oct; 33(4A):541-5. PubMed ID: 2811363
    [Abstract] [Full Text] [Related]

  • 46. Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide.
    Lønning PE, Johannessen DC, Thorsen T.
    Br J Cancer; 1989 Jul; 60(1):107-11. PubMed ID: 2553085
    [Abstract] [Full Text] [Related]

  • 47. First generation aromatase inhibitors--aminoglutethimide and testololactone.
    Cocconi G.
    Breast Cancer Res Treat; 1994 Jul; 30(1):57-80. PubMed ID: 7949205
    [Abstract] [Full Text] [Related]

  • 48. Aromatase inhibitors: clinical pharmacology and therapeutic implications in breast cancer.
    Pérez N, Borja J.
    J Int Med Res; 1992 Aug; 20(4):303-12. PubMed ID: 1387368
    [Abstract] [Full Text] [Related]

  • 49. Effect of treatment with 4-hydroxyandrostenedione on the peripheral conversion of androstenedione to estrone and in vitro tumor aromatase activity in postmenopausal women with breast cancer.
    Reed MJ, Lai LC, Owen AM, Singh A, Coldham NG, Purohit A, Ghilchik MW, Shaikh NA, James VH.
    Cancer Res; 1990 Jan 01; 50(1):193-6. PubMed ID: 2293555
    [Abstract] [Full Text] [Related]

  • 50. Influence of dexaminoglutethimide, an optical isomer of aminoglutethimide, on the disposition of estrone sulfate in postmenopausal breast cancer patients.
    Geisler J, Lundgren S, Berntsen H, Greaves JL, Lønning PE.
    J Clin Endocrinol Metab; 1998 Aug 01; 83(8):2687-93. PubMed ID: 9709932
    [Abstract] [Full Text] [Related]

  • 51. Aromatase inhibitors and the treatment of breast cancer.
    Brodie AM, Wing LY, Goss P, Dowsett M, Coombes RC.
    J Steroid Biochem; 1986 Jan 01; 24(1):91-7. PubMed ID: 3702431
    [Abstract] [Full Text] [Related]

  • 52. Introduction to the conference, Aromatase: New Perspectives for Breast Cancer.
    Santen RJ.
    Cancer Res; 1982 Aug 01; 42(8 Suppl):3268s. PubMed ID: 7083183
    [No Abstract] [Full Text] [Related]

  • 53. Aminoglutethimide enzyme induction: pharmacological and endocrinological implications.
    Lønning PE.
    Cancer Chemother Pharmacol; 1990 Aug 01; 26(4):241-4. PubMed ID: 2369789
    [Abstract] [Full Text] [Related]

  • 54. Estrogen synthesis in human breast tumor and its inhibition by testololactone and bromoandrostenedione.
    Dao TL.
    Cancer Res; 1982 Aug 01; 42(8 Suppl):3338s-3341s. PubMed ID: 7083197
    [Abstract] [Full Text] [Related]

  • 55. Endocrine and clinical endpoints of exemestane as neoadjuvant therapy.
    Miller WR, Dixon JM.
    Cancer Control; 2002 Aug 01; 9(2 Suppl):9-15. PubMed ID: 11965226
    [Abstract] [Full Text] [Related]

  • 56. Induction of aromatase expression by aminoglutethimide, an aromatase inhibitor that is used to treat breast cancer in postmenopausal women.
    Kao YC, Okubo T, Sun XZ, Chen S.
    Anticancer Res; 1999 Aug 01; 19(3A):2049-56. PubMed ID: 10470147
    [Abstract] [Full Text] [Related]

  • 57. Closing remarks to the conference, Aromatase: New Perspectives for Breast Cancer.
    Lipton A, Harvey HA, Santen RJ.
    Cancer Res; 1982 Aug 01; 42(8 Suppl):3468s. PubMed ID: 7083210
    [No Abstract] [Full Text] [Related]

  • 58. Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer.
    Miller WR, Stuart M, Sahmoud T, Dixon JM.
    Br J Cancer; 2002 Oct 21; 87(9):950-5. PubMed ID: 12434282
    [Abstract] [Full Text] [Related]

  • 59. Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels.
    Geisler J, Haynes B, Ekse D, Dowsett M, Lønning PE.
    J Steroid Biochem Mol Biol; 2007 Apr 21; 104(1-2):27-34. PubMed ID: 17350249
    [Abstract] [Full Text] [Related]

  • 60. Aminoglutethimide as an aromatase inhibitor in the treatment of cancer.
    Santen RJ.
    Cancer Treat Rev; 1984 Dec 21; 11(4):325-9. PubMed ID: 6534513
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.